Patent ID: 6384069
Filing Date: 2002-05-07
Classification: A61P,C07D

Abstract:
A method of treating disorders caused by an elevated extracellular glutamate level, wherein the disorder is selected from the group consisting of stroke, chronic pain, hypoglycemia, hypoxia, trauma, Alzheimer's disease, AIDS-associated dementia, amyotrophic lateral sclerosis, Parkinson's disease, and chronic alcoholism, comprising administering to a patient in need thereof a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a 2-pyrrolidinone derivative of the general formula: in whichR1 and R2 are, independently of one another, hydrogen atoms, hydroxyl groups, amino groups, C1-C10 alkoxy radicals, C1-C10 alkyl radicals or C1-C10 alkyl-amino radicals, or R1 and R2 together with the carbon atom in position 4 of the pyrrolidinone ring form a five- to ten-membered saturated or unsaturated ring which, besides carbon atoms, may have up to 2 heteroatoms selected from oxygen, sulfur and nitrogen atoms, and which is unsubstituted or is substituted by up to 3 substituents selected from hydroxyl groups, amino groups, C1-C4 alkyl radicals, C1-C4 alkoxy radicals and C1-C4 alkylamino radicals, with the proviso that R1 and R2 are not both hydrogen atoms, R3, R4, R5 and R6 are, each independently of one another, hydrogen atoms, halogen atoms, hydroxyl groups, amino groups, C1-C10 alkyl radicals, C1-C10 alkoxy radicals, C1-C10 alkylamino radicals or C6-C10 aryl radicals, and R7 is a hydrogen atom or a C1-C10 aryl radical or C1-C10 acyl radical, or a pharmacologically acceptable salt thereof.